Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | SNCA | P37840 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822865 | 1.00 | MAPT (0.58) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL3811532 | 1.00 | MAPT (0.58) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL28645847 | 0.90 | MAOA (0.53) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL28645848 | 0.90 | MAOA (0.53) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL29624601 | 0.90 | MAOA (0.53) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL11887911 | 0.89 | CCNB2 (0.62) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL4989076 | 0.88 | PLK4 (0.62) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL4987965 | 0.88 | PLK4 (0.62) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL4994853 | 0.88 | ALDH1A1 (0.53) | MAPTALDH1A1NPSR1KDM4EPKM | |
| SCHEMBL4999350 | 0.88 | ALDH1A1 (0.58) | MAPTALDH1A1NPSR1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | claimed |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-03-23 | — | — | US | claimed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | claimed |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ANDREWS STEVEN W (US) | 2004-10-07 | — | — | US | claimed |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-12-04 | — | — | US | claimed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | claimed |
| EP-1986750-B1 | Use of an extract of Enanthia Chloranta | SEDERMA SA (FR) | 2019-04-24 | — | — | EP | disclosed |
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-9233070-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9056045-B2 | Intraocular biodegradable microspheres | ALLERGAN, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| WO-2004078157-A2 | REGULATION OF MAMMALIAN HAIR GROWTH | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-16 | — | — | WO | disclosed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MAPT 3370/4885ALDH1A1 1651/4885NPSR1 2694/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | MAPT 2317/4885ALDH1A1 4171/4885NPSR1 2240/4885 |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | MAPT 35/4885ALDH1A1 2148/4885NPSR1 4541/4885 |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MAPT 3370/4885ALDH1A1 1651/4885NPSR1 2694/4885 |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MAPT 3370/4885ALDH1A1 1651/4885NPSR1 2694/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | MAPT 826/4885ALDH1A1 1537/4885NPSR1 1525/4885 |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MAPT 3370/4885ALDH1A1 1651/4885NPSR1 2694/4885 |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MAPT 3370/4885ALDH1A1 1651/4885NPSR1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.